Close Menu

Jeanne Whalen at the Wall Street Journal examines the restructuring of R&D at GlaxoSmithKline, and other big drug companies, over the past decade. GSK "has carved its research group into dozens of such small units" in an effort to "turn a sluggish, bureaucratic R&D staff into a constellation of specialized teams capable of discovering cutting-edge drugs — much in the way biotech companies do,"she writes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.